Emcure Takes Full Control of Gennova in 12% Stake Buy

The acquisition removes a minority shareholder layer that complicated decision-making at Gennova, which had operated as a separate entity within the Emcure group. Full ownership lets Emcure allocate capital and resources to Gennova without negotiation with outside holders.

Gennova's pipeline includes vaccines and biologics targeting infectious diseases. The mRNA divestiture signals a narrower focus on protein-based biologics and existing platform technologies. Emcure did not disclose the financial terms of the stake purchase.